We are live on ! Find out more

Drug Manufacturers - General
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
LLY icon
1
Eli Lilly
LLY
$1.2T
$1.2T $1,351.12 2.29%
JNJ icon
2
Johnson & Johnson
JNJ
$643B
$643B $267.14 2.04%
ABBV icon
3
AbbVie
ABBV
$501B
$501B $283.54 0.86%
MRK icon
4
Merck
MRK
$327B
$327B $132.81 3.61%
NVS icon
5
Novartis
NVS
$286B
$286B $151.22 2.57%
AZN icon
6
AstraZeneca
AZN
$272B
$272B $175.41 1.87%
AMGN icon
7
Amgen
AMGN
$237B
$237B $438.82 1.14%
GILD icon
8
Gilead Sciences
GILD
$207B
$207B $166.53 1.45%
NVO icon
9
Novo Nordisk
NVO
$171B
$171B $38.87 1.42%
PFE icon
10
Pfizer
PFE
$157B
$157B $27.54 1.85%
BMY icon
11
Bristol-Myers Squibb
BMY
$119B
$119B $58.34 2.05%
SNY icon
12
Sanofi
SNY
$111B
$111B $46.06 2.25%
GSK icon
13
GSK
GSK
$95.9B
$95.9B $47.82 1.56%
BIIB icon
14
Biogen
BIIB
$36.5B
$36.5B $247.13 1.7%
GRFS icon
15
Grifois
GRFS
$5.58B
$5.58B $8.20 3.19%
OGN icon
16
Organon & Co
OGN
$3.65B
$3.65B $13.91 0.07%
AMRN icon
17
Amarin
AMRN
$473M
$473M $11.26 0%
PLX icon
18
Protalix BioTherapeutics
PLX
$258M
$258M $3.06 1.32%
LCTX icon
19
Lineage Cell Therapeutics
LCTX
$207M
$207M $0.8200 2.21%
ARMP icon
20
Armata Pharmaceuticals
ARMP
$111M
$111M $2.98 5.99%
MAIA icon
21
MAIA Biotechnology
MAIA
$70.4M
$70.4M $1.14 12.3%
OSTX icon
22
OS Therapies
OSTX
$42.9M
$42.9M $0.8204 10.8%
SDEV icon
23
Stablecoin Development
SDEV
$40.8M
$40.8M $0.5574 7.01%
ATNM icon
24
Actinium Pharmaceuticals
ATNM
$33.6M
$33.6M $1.07 0.93%
SER icon
25
Serina Therapeutics
SER
$31.9M
$31.9M $1.20 11.1%

Drug Manufacturers - General Stocks at a Glance

Large drug manufacturers sell diversified portfolios of branded medicines backed by deep development pipelines. Patent lives set the clock: blockbuster franchises fund the R&D and acquisitions needed to outrun expirations, supporting durable margins and dividends.

There are 46 Drug Manufacturers - General industry stocks tracked by Wall St. Rank, worth a combined $4.38T.

The largest by market cap are Eli Lilly (LLY) at $1.2T, Johnson & Johnson (JNJ) at $643B and AbbVie (ABBV) at $501B.

Among institutional investors, Merck (MRK) drew the most net new fund positions in Q3 2026: 306 funds opened new positions, taking total fund holders up 95 (2.4%) quarter-over-quarter.

  • Combined market cap: $4.38T across 46 stocks.
  • Largest constituent: Eli Lilly (LLY), $1.2T market cap.
  • Most net new fund positions in Q3 2026: Merck (MRK), +95 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q3 2026.